Merck & Co. Inc. is pledging major resources on its prospect in the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor space with a phase III program that together will enroll about 17,000 subjects and test oral peptide MK-0616’s effect on tackling low-density lipoprotein cholesterol.
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results
Dr. Justice S. Muralidhar, Chief Justice of the Orissa High Court has announced that 100 more paperless Courts shall be opened across various districts of Odisha within the next three months. In.
significantly slowed cognitive decline. according to the company s latest clinical trials, some people who took the drug slowed their decline by up to 35% compared to those who took a placebo. the study included 1,700 participants between the age of 60 and 85. joining us now is meg terrell. this means so much to so many people. we ve seen how many people are struggling with this. the question is, how legit is this study? it s extremely legit. in terms of running clinical trials, a phase iii placebo-controlled study is the gold standard. this was run with a lot of patients. lily will use this to file for fda approval this quarter. what this drug does is it s the latest in a new group that is successfully removing amyloid plaques from the brain. you can see in this graphic, the top two images are patients on this drug. this is an earlier study. over the course of 76 weeks, that plaque buildup in the